q3 adjusted loss per share $0.61 excluding items.
q1 loss per share $1.76.
qtrly medical end-use sales were down 3% sequentially as customers continue to manage inventory levels as concerns around hospital capacity and potential resurgence weighed on supply chain.
q2 sales $348.8 million versus refinitiv ibes estimate of $352.4 million.
for the balance of year, company currently expects its tax rate to be in range of 28% to 32% for full year 2021.
q1 adjusted operating loss per share $32.3.
qtrly sales excluding surcharge decreased 3% sequentially.
qtrly sales excluding surcharge decreased 34% on 32% lower volume.